Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 4/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ADIPOR2 | Q86V24 | 1/20 | 0.56 |
| ▸ | ADIPOR1 | Q96A54 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19692540 | 0.90 | ATF4 (1.00) | ATF4POLBALDH1A1LMNAKMT2A | |
| SCHEMBL19705224 | 0.88 | ATF4 (0.78) | ATF4POLBALDH1A1ADIPOR2ADIPOR1 | |
| SCHEMBL19705112 | 0.87 | ATF4 (0.79) | ATF4POLBALDH1A1ADIPOR2ADIPOR1 | |
| SCHEMBL19692580 | 0.86 | ATF4 (0.62) | ATF4POLBALDH1A1ADIPOR2ADIPOR1 | |
| SCHEMBL16082988 | 0.86 | ATF4 (1.00) | ATF4ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL16083047 | 0.86 | ATF4 (1.00) | ATF4ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL16082980 | 0.86 | ATF4 (1.00) | ATF4ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL19692560 | 0.85 | ATF4 (0.82) | ATF4POLBALDH1A1ADIPOR2ADIPOR1 | |
| SCHEMBL19709169 | 0.85 | ATF4 (0.86) | ATF4POLBALDH1A1LMNAKMT2A | |
| SCHEMBL21819632 | 0.85 | ATF4 (1.00) | ATF4POLBALDH1A1ADIPOR2ADIPOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103068797-A | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | SANOFI SA | 2013-04-24 | — | — | CN | disclosed |
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | ATF4 893/4885POLB 2244/4885ALDH1A1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.